AP1903

Research use only, not for human use.

AP1903 (Rimiducid, AP-1903) is a potent, specific synthetic ligand of FKBP Phe36Val mutant (F36V-FKBP) with binding IC50 of 1.8 nM.

AP1903 (Rimiducid, AP-1903) is a potent, specific synthetic ligand of FKBP Phe36Val mutant (F36V-FKBP) with binding IC50 of 1.8 nM; displaces the Fluoresceinated FK506 probe from F36V-FKBP with an IC50 of 5 nM, but shows negligible binding activity to the wild-type protein; elicited potent and dose-dependent apoptotic death of human fibrosarcoma line HT1080 expressing dimerizer-dependent Fas constructs with EC50 of 0.1 nM; induces activation of Fas signaling both in vitro and in vivo, AP1903 is a lipid-permeant dimerizing ligand induced oligomerization and activation of FKBP.Blood Cancer Phase 3 Clinical

Rimiducid;AP-1903

Others

Other Targets

Other Targets

Cancer

Blood cancer

195514-63-7

1411.65

C78H98N4O20

>98% (HPLC)

DMSO : ≥ 54 mg/mL 38.25 mM

O=C([C@H]1N(C([C@H](C2=CC(OC)=C(OC)C(OC)=C2)CC)=O)CCCC1)O[C@@H](C3=CC=CC(OCC(NCCNC(COC4=CC=CC([C@H](OC([C@H]5N(C([C@H](C6=CC(OC)=C(OC)C(OC)=C6)CC)=O)CCCC5)=O)CCC7=CC=C(OC)C(OC)=C7)=C4)=O)=O)=C3)CCC8=CC=C(OC)C(OC)=C8

(S,2R,2'R)-(1R,1'R)-((((ethane-1,2-diylbis(azanediyl))bis(2-oxoethane-2,1-diyl))bis(oxy))bis(3,1-phenylene))bis(3-(3,4-dimethoxyphenyl)propane-1,1-diyl) bis(1-((S)-2-(3,4,5-trimethoxyphenyl)butanoyl)piperidine-2-carboxylate)

(-20℃)

With Ice Pack

≥ 2 years